Percutaneous Coronary Intervention

Cardiovascular
5
Pipeline Programs
7
Companies
8
Clinical Trials
3
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
4
Early DiscoveryClinical DevelopmentMarket

On Market (3)

Approved therapies currently available

U
IOPAMIDOLApproved
iopamidol
Unknown Company
Radiographic Contrast Agent [EPC]injection2023
U
SCANLUX-300Approved
iopamidol
Unknown Company
injection2010
U
SCANLUX-370Approved
iopamidol
Unknown Company
injection2010

Competitive Landscape

7 companies ranked by most advanced pipeline stage

Acist Medical Systems
Acist Medical SystemsMN - Eden Prairie
2 programs
1
IopamidolPhase 41 trial
Transradial PCIN/A
Active Trials
NCT03557385CompletedEst. Apr 2023
RION
RIONMN - Rochester
1 program
1
PEPPhase 11 trial
Active Trials
NCT04327635CompletedEst. Oct 2025
Abbott
AbbottABBOTT PARK, IL
3 programs
LithoplastyN/A1 trial
Stent delivery with XpeditionN/A1 trial
Transradial PCIN/A1 trial
Active Trials
NCT04253171Completed200Est. Nov 2025
NCT03451617Unknown500Est. Oct 2020
NCT01406236Terminated1,787Est. Sep 2013
CathWorks
CathWorksCA - Newport Beach
1 program
FFRangioN/A1 trial
Active Trials
NCT05893498Active Not RecruitingEst. Jan 2026
DS
Daiichi SankyoChina - Shanghai
1 program
Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet InhibitionN/A1 trial
Active Trials
NCT01582217Completed318Est. Dec 2014
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Procedure: PCIN/A1 trial
Active Trials
NCT01841346Completed2,000Est. Feb 2015
Guerbet
GuerbetFrance - Villepinte
1 program
Transradial PCIN/A

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Acist Medical SystemsIopamidol
RIONPEP
CathWorksFFRangio
AbbottLithoplasty
AbbottStent delivery with Xpedition
AstraZenecaProcedure: PCI
Daiichi SankyoPatients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition
AbbottTransradial PCI

Clinical Trials (8)

Total enrollment: 4,805 patients across 8 trials

NCT03557385Acist Medical SystemsIopamidol

Adenosine Contrast CorrELations in Evaluating RevAscularizaTION

Start: Jan 2019Est. completion: Apr 2023
Phase 4Completed
NCT04327635RIONPEP

Safety Evaluation of Intracoronary Infusion of Extracellular Vesicles in Patients Following Coronary Stent Implantation

Start: Nov 2021Est. completion: Oct 2025
Phase 1Completed
NCT05893498CathWorksFFRangio

Advancing Cath Lab Results With FFRangio Coronary Physiology Assessment

Start: Jun 2023Est. completion: Jan 2026
N/AActive Not Recruiting
NCT04253171AbbottLithoplasty

Balloon Lithoplasty for Preparation of Severely Calcified Coronary Lesions

Start: Jan 2020Est. completion: Nov 2025200 patients
N/ACompleted
NCT03451617AbbottStent delivery with Xpedition

Alpine vs. Xpedition: Evaluation of Stent Delivery System

Start: Oct 2017Est. completion: Oct 2020500 patients
N/AUnknown
NCT01841346AstraZenecaProcedure: PCI

The First Jordanian PCI Registry: Events at 1 Year

Start: Mar 2013Est. completion: Feb 20152,000 patients
N/ACompleted
NCT01582217Daiichi SankyoPatients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

Patients Undergoing Percutaneous Coronary Intervention (PCI) Through Optimal Platelet Inhibition

Start: Mar 2012Est. completion: Dec 2014318 patients
N/ACompleted
NCT01406236AbbottTransradial PCI

SAFE-PCI for Women

Start: Aug 2011Est. completion: Sep 20131,787 patients
N/ATerminated

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
Yesterday
From $150K/yr

Associate Regulatory Affairs Specialist

Medtronic
Mounds View, Minnesota, United States of America
Yesterday
$60K - $90K/yr

Business Development Manager, Post Transplant, Cardio Thoracic

Thermo Fisher Scientific
Remote
Yesterday

Director, Medical Affairs

Abbott
Germany - Hesse - Eschborn
Yesterday

Therapy Development Manager

Abbott
Australia > Doncaster : 666 Doncaster Road
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)